| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5164 | 2014 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2587 | 2016 |
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... New England Journal of Medicine 359 (9), 906-917, 2008 | 2478 | 2008 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863-2869, 2015 | 2209 | 2015 |
| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1693 | 2016 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1603 | 2015 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1532 | 2015 |
| Targeting CD38 with daratumumab monotherapy in multiple myeloma HM Lokhorst, T Plesner, JP Laubach, H Nahi, P Gimsing, M Hansson, ... New England Journal of Medicine 373 (13), 1207-1219, 2015 | 1297 | 2015 |
| Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma P Moreau, T Masszi, N Grzasko, NJ Bahlis, M Hansson, L Pour, I Sandhu, ... New England Journal of Medicine 374 (17), 1621-1634, 2016 | 1241 | 2016 |
| Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ... Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011 | 1135 | 2011 |
| Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial A Palumbo, S Bringhen, T Caravita, E Merla, V Capparella, V Callea, ... The Lancet 367 (9513), 825-831, 2006 | 1064 | 2006 |
| Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and … RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ... Leukemia 24 (6), 1121-1127, 2010 | 1047 | 2010 |
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hajek, ... Leukemia 23 (2), 215-224, 2009 | 1041 | 2009 |
| Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008 | 1035 | 2008 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1028 | 2013 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 1005 | 2016 |
| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem … M Cavo, P Tacchetti, F Patriarca, MT Petrucci, L Pantani, M Galli, ... The Lancet 376 (9758), 2075-2085, 2010 | 983 | 2010 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 960 | 2012 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 955 | 2016 |
| Continuous lenalidomide treatment for newly diagnosed multiple myeloma A Palumbo, R Hajek, M Delforge, M Kropff, MT Petrucci, J Catalano, ... New England Journal of Medicine 366 (19), 1759-1769, 2012 | 921 | 2012 |
Mario BoccadoroEmeritus Professor of Hematology, University of Torino, Italy在 unito.it 的电子邮件经过验证
